AFP
SCMP

Ausdal Financial Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Ausdal Financial Partners’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,000
Closed -$35K – 1211
2015
Q4 		$35K Buy
+2,000
New +$35.9K 0.02% 561

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Ausdal Financial Partners's SCMP Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2016, closing a stake of 2,000 shares — an estimated $35K sold.

Ausdal Financial Partners first reported a position in SCMP in Q4 2015 and held it in 1 quarter. The position peaked at $35K in Q4 2015. 134 funds tracked by Wall St. Rank hold SCMP as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 2,000 Sucampo Pharmaceuticals, Inc. shares in Q1 2016, an estimated $35K.
  • Ausdal Financial Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Sucampo Pharmaceuticals, Inc. position peaked at $35K in Q4 2015.
  • 134 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.